A patented gel in a new condom promises to boost lovemaking by promoting blood flow.
The gel inside the tip of the sheath rapidly permeates the skin to boost blood flow, giving men a welcome lift.
The Zanifil gel is based on nitroglycerin used in treating chest pain and heart failure since the 19th century. "It's essentially Viagra in a condom," Daniel Mahony told Bloomberg.
However, unlike Pfizer's Viagra, the condom will be available without prescription. There is no word yet from Durex, the manufacturer, on how much a packet will set you back, the Daily Mail reports.
The condom, known as CSD500, was awarded a CE mark in August this year, which means it can be sold across Europe in the same way as conventional condoms.
It followed a double-blind clinical trial that compared the CSD500 to a standard condom. A majority of testers reported improvements in their erection and penis size when using the new product, while many women reported a longer-lasting sexual experience.
The condom is likely to be a big business for both Futura and distributor Reckitt Benckiser, which owns Durex. Sales of Viagra have rocketed to 1.2 billion pounds since it was launched as a drug for erectile dysfunction in 1998.
A spokesman for Futura said: "The commercial potential of CSD500 is obvious with one in 10 men in the world having erectile dysfunction."
"However, CSD500 differs from erectile dysfunction drugs like Viagra because it is specifically aimed at men who struggle to maintain an erection whilst wearing a condom."
The gel inside the tip of the sheath rapidly permeates the skin to boost blood flow, giving men a welcome lift.
The Zanifil gel is based on nitroglycerin used in treating chest pain and heart failure since the 19th century. "It's essentially Viagra in a condom," Daniel Mahony told Bloomberg.
However, unlike Pfizer's Viagra, the condom will be available without prescription. There is no word yet from Durex, the manufacturer, on how much a packet will set you back, the Daily Mail reports.
The condom, known as CSD500, was awarded a CE mark in August this year, which means it can be sold across Europe in the same way as conventional condoms.
It followed a double-blind clinical trial that compared the CSD500 to a standard condom. A majority of testers reported improvements in their erection and penis size when using the new product, while many women reported a longer-lasting sexual experience.
The condom is likely to be a big business for both Futura and distributor Reckitt Benckiser, which owns Durex. Sales of Viagra have rocketed to 1.2 billion pounds since it was launched as a drug for erectile dysfunction in 1998.
A spokesman for Futura said: "The commercial potential of CSD500 is obvious with one in 10 men in the world having erectile dysfunction."
"However, CSD500 differs from erectile dysfunction drugs like Viagra because it is specifically aimed at men who struggle to maintain an erection whilst wearing a condom."
0 comments:
Please add comment to express your opinion, and share it on Twitter or Facebook. Thank you in advance.